These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Psilocybin--summary of knowledge and new perspectives. Tylš F; Páleníček T; Horáček J Eur Neuropsychopharmacol; 2014 Mar; 24(3):342-56. PubMed ID: 24444771 [TBL] [Abstract][Full Text] [Related]
8. [Classic psychedelic drugs and their potential therapeutic effect]. Bayat M Ugeskr Laeger; 2017 Sep; 179(37):. PubMed ID: 28918777 [TBL] [Abstract][Full Text] [Related]
9. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Vollenweider FX; Kometer M Nat Rev Neurosci; 2010 Sep; 11(9):642-51. PubMed ID: 20717121 [TBL] [Abstract][Full Text] [Related]
10. Serotonergic Psychedelics: Experimental Approaches for Assessing Mechanisms of Action. Canal CE Handb Exp Pharmacol; 2018; 252():227-260. PubMed ID: 29532180 [TBL] [Abstract][Full Text] [Related]
11. Psychedelic drugs-a new era in psychiatry? . Nutt D Dialogues Clin Neurosci; 2019; 21(2):139-147. PubMed ID: 31636488 [TBL] [Abstract][Full Text] [Related]
12. Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences? Majić T; Schmidt TT; Gallinat J J Psychopharmacol; 2015 Mar; 29(3):241-53. PubMed ID: 25670401 [TBL] [Abstract][Full Text] [Related]
14. Unique and potent effects of acute ibogaine on zebrafish: the developing utility of novel aquatic models for hallucinogenic drug research. Cachat J; Kyzar EJ; Collins C; Gaikwad S; Green J; Roth A; El-Ounsi M; Davis A; Pham M; Landsman S; Stewart AM; Kalueff AV Behav Brain Res; 2013 Jan; 236(1):258-269. PubMed ID: 22974549 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress. Ross S Int Rev Psychiatry; 2018 Aug; 30(4):317-330. PubMed ID: 30102082 [TBL] [Abstract][Full Text] [Related]
16. Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions. Garcia-Romeu A; Richards WA Int Rev Psychiatry; 2018 Aug; 30(4):291-316. PubMed ID: 30422079 [TBL] [Abstract][Full Text] [Related]
17. Advances and pathophysiological models of hallucinogenic drug actions in humans: a preamble to schizophrenia research. Vollenweider FX Pharmacopsychiatry; 1998 Jul; 31 Suppl 2():92-103. PubMed ID: 9754840 [TBL] [Abstract][Full Text] [Related]
18. A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses. Chi T; Gold JA J Neurol Sci; 2020 Apr; 411():116715. PubMed ID: 32044687 [TBL] [Abstract][Full Text] [Related]
19. Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms. Inserra A; De Gregorio D; Gobbi G Pharmacol Rev; 2021 Jan; 73(1):202-277. PubMed ID: 33328244 [TBL] [Abstract][Full Text] [Related]
20. Psychedelic medicine: The biology underlying the persisting psychedelic effects. Kuypers KPC Med Hypotheses; 2019 Apr; 125():21-24. PubMed ID: 30902145 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]